Editorial: Strategies aimed at improving the effectiveness of immunotherapies in pediatric brain cancer

Understanding the immune landscape of pediatric brain tumors is essential for developing effective immunotherapies. Chen et al. profiled medulloblastoma (MB) subgroups WNT, SHH, Group 3, and Group 4 revealing distinct immune cell infiltration patterns. Group 3 tumors showed elevated CD8+ T cells, Tregs, and endothelial cells. Three hub genes (GAB1, CXCR4, ABL1) were identified as potential biomarkers linked to immune checkpoint responsiveness and drug sensitivity, supporting subgroup-specific immunotherapy strategies. Bhargav et al. highlighted the importance of modeling the pediatric brain tumor microenvironment to improve translational relevance. Their review outlines advanced platforms organoids, organotypic brain slices, and 3D bioengineered systems that better replicate immune-tumor interactions. These models are essential for evaluating immunotherapies and overcoming barriers in MB and glioma. b) CAR-T Cell Therapy: Overcoming Trafficking and Persistence Barriers CAR-T cell therapy holds promise for pediatric brain malignancies but faces significant challenges. Yaacoub et al. reviewed two major obstacles: poor trafficking across the blood-brain barrier (BBB) and limited persistence in the immunosuppressive tumor microenvironment. They discussed locoregional delivery methods, focused ultrasound, and biomaterials to enhance trafficking, alongside CAR engineering strategies co-stimulatory domains, cytokine support, and checkpoint inhibition to improve persistence and efficacy. Cross This Research Topic brings together diverse yet interconnected strategies aimed at improving the effectiveness of immunotherapies in pediatric brain cancer. From molecular profiling and preclinical modeling to CAR-T engineering and neoantigen targeting, the contributions reflect a maturing field that is increasingly data-driven, mechanistically informed, and clinically ambitious. The collective insights emphasize the importance of tailoring immunotherapy to the unique biology of pediatric brain tumors, leveraging subgroup-specific vulnerabilities, and overcoming the structural and immunological barriers of the CNS. Continued innovation in delivery methods, cell engineering, and model systems will be essential to translate these advances into durable clinical benefit.